Literature DB >> 3490435

Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.

S Hinuma, K Naruo, O Shiho, K Tsukamoto.   

Abstract

We have examined the induction of murine non-specific killer cells in vivo and in vitro by purified recombinant human interleukin-2 (rIL-2), and compared their characteristics with respect to killing ability, cell surface phenotypes, and antibody-dependent cell-mediated cytotoxicity (ADCC). C57BL/6 spleen cells cultured with rIL-2 were remarkably cytotoxic against a variety of tumour cells in a 4-hr 51Cr-release assay. Treatment with various antibodies (anti-Thy 1, anti-Lyt 1, anti-Lyt 2, and anti-asialo GM1) plus complement (C) showed that anti-Thy 1 or anti-asialo GM1 antibody plus C removed a majority of killer activity (80% and 66%, respectively). In addition, an increase in ADCC was detected in the spleen cells cultured with rIL-2. These ADCC effector cells were indistinguishable from non-specific killer cells by the cell surface phenotypes. A single administration of rIL-2 in vivo induced only transient and marginal enhancement of non-specific killer activity of spleen cells in C57BL/6 mice. On the other hand, when 10 micrograms of rIL-2 were administered daily by bolus to C57BL/6 mice, the activity increased gradually for about 10 days and reached a plateau. This enhanced non-specific killer activity rapidly decreased and returned to normal by 72 hr after the administration was stopped. The non-specific killer cells induced in vivo in this manner were not only greatly cytotoxic against natural killer (NK)-sensitive tumour cells but were also significantly cytotoxic against NK-resistant tumour cells. Most of the killer activity (more than 90%) was specifically removed by treatment with anti-Thy 1 or anti-asialo GM1 antibody plus C. An increase in ADCC was detected concurrently with an increase in non-specific killer activity in vivo, and both effector cells were indistinguishable by their cell surface phenotypes. These results indicate that a majority of non-specific killer cells induced both in vivo and in vitro by rIL-2 have some common features. Our results also suggest that these cells belong to the same lineage as NK cells, although they are thought to be at different stages from resident NK cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490435      PMCID: PMC1453159     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  20 in total

1.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  K Kato; T Yamada; K Kawahara; H Onda; T Asano; H Sugino; A Kakinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

2.  Heterogeneity of human T-cell growth factor(s) due to variable glycosylation.

Authors:  R J Robb; K A Smith
Journal:  Mol Immunol       Date:  1981-12       Impact factor: 4.407

3.  Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.

Authors:  K Itoh; A B Tilden; K Kumagai; C M Balch
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

4.  In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice.

Authors:  S Habu; H Fukui; K Shimamura; M Kasai; Y Nagai; K Okumura; N Tamaoki
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

5.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

Authors:  M Rosenstein; I Yron; Y Kaufmann; S A Rosenberg
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

6.  Comparison of the biological properties of purified natural and recombinant human interleukin-2.

Authors:  K Naruo; S Hinuma; K Kato; M Koyama; H Tada; O Shiho; K Tsukamoto
Journal:  Biochem Biophys Res Commun       Date:  1985-04-16       Impact factor: 3.575

7.  Purification and partial sequence analysis of human interleukin-2 derived from peripheral blood leukocytes.

Authors:  K Kato; K Naruo; M Koyama; K Kawahara; S Hinuma; H Tada; H Sugino; K Tsukamoto
Journal:  Biochem Biophys Res Commun       Date:  1985-02-28       Impact factor: 3.575

8.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

9.  Systemic administration of recombinant human interleukin-2 in mice.

Authors:  A E Chang; C L Hyatt; S A Rosenberg
Journal:  J Biol Response Mod       Date:  1984-10

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  17 in total

1.  Killer cells induced by stimulation with allogeneic tumor cells and subsequent culture with recombinant interleukin-2.

Authors:  T Fukiage; H Murakami; M Eura; T Ikawa; T Ishikawa
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.

Authors:  K I Naruo; S Hinuma; O Shiho; T Houkan; K Ootsu; K Tsukamoto
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

3.  Experimental study on multidisciplinary treatment of pancreatic cancer.

Authors:  T Moriai; T Takeba; I Makino
Journal:  Int J Pancreatol       Date:  1990-04

4.  Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.

Authors:  S Yamaguchi; M Onji; H Kondoh; H Miyaoka; Y Ohta
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

5.  Differential augmentation of in vivo natural killer cytotoxicity in normal primates with recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor.

Authors:  T A Davis; R L Monroy; R R Skelly; R E Donahue; T J MacVittie
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

6.  Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Authors:  K Ootsu; K Gotoh; T Houkan
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Activation of swine peripheral blood lymphocytes with human recombinant interleukin-2.

Authors:  R C Bhagyam; D Jarrett-Zaczek; F G Ferguson
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

8.  Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.

Authors:  Y Iizawa; T Nishi; M Kondo; K Tsuchiya; A Imada
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

9.  Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.

Authors:  S Hinuma; K Naruo; K Ootsu; T Houkan; O Shiho; K Tsukamoto
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

10.  Augmentative effect of Nocardia rubra cell-wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction.

Authors:  S Yokota; T Shirasaka; H Nishikawa; S Hosoe; T Ikeda; K Komuta; I Kawase; T Masuno; T Ogura; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.